Metro Center for Respiratory Diseases (MCRD), Metro Multispeciality Hospital, Noida, 201301, India.
Metro Center for Respiratory Diseases (MCRD), Metro Multispeciality Hospital, Noida, 201301, India.
Indian J Tuberc. 2021 Apr;68(2):261-265. doi: 10.1016/j.ijtb.2020.09.010. Epub 2020 Sep 16.
Bronchiectasis severity Index (BSI) score which predicts the severity of the disease along with future exacerbations and mortality rate has been well validated in European patients; however there is paucity of data evaluating its validity in Indian patients. The authors therefore decided to evaluate the utility of BSI to predict exacerbations and mortality rate in patients with post tubercular bronchiectasis presenting to our facility.
The study was a retrospective observational study done in patients with bronchiectasis secondary to tuberculosis. These patients were followed up for 4 years. BSI was calculated from different variables and descriptive statistics along with regression analysis were used to evaluate utility of BSI.
A total of 48 patients of post tubercular bronchiectasis were included in the study. Majority of our patients belonged to severe bronchiectasis group seen in 23 patients (48%) while those with mild and moderate bronchiectasis were seen in 13 (27%) and 12 (25%) patients respectively. The exacerbation rate in mild group was comparable to the predicted BSI exacerbation at 1 year while the predicted and observed rates were statistically significant for moderate and severe bronchiectasis group (p value < 0.05). Mortality rates at 1 year were comparable in all the groups of bronchiectasis while it was comparable only in mild and moderate group bronchiectasis at 4 years.
Bronchiectasis severity index seems to predict mortality at 1 year in post tuberculosis bronchiectasis. However, it under predicts 1 year and 4 year exacerbation rates. Hence BSI may not be useful as a prognostic tool in Indian patients with bronchiectasis. Larger multi-centred studies may be required to further evaluate the clinical utility of BSI among Indian population.
支气管扩张严重指数(BSI)评分可预测疾病严重程度以及未来加重和死亡率,在欧洲患者中已得到充分验证;然而,评估其在印度患者中的有效性的数据很少。因此,作者决定评估 BSI 在我院就诊的肺结核后支气管扩张患者中预测加重和死亡率的效用。
这是一项针对肺结核后支气管扩张患者的回顾性观察性研究。这些患者接受了 4 年的随访。从不同变量计算 BSI,并使用描述性统计和回归分析来评估 BSI 的效用。
共有 48 例肺结核后支气管扩张患者纳入研究。我们的大多数患者属于严重支气管扩张组,有 23 例(48%);轻度和中度支气管扩张分别有 13 例(27%)和 12 例(25%)。轻度组的加重率与预测的 1 年 BSI 加重率相当,而中度和重度支气管扩张组的预测和观察率具有统计学意义(p 值<0.05)。1 年时,所有支气管扩张组的死亡率相当,而 4 年时仅在轻度和中度组支气管扩张中相当。
在肺结核后支气管扩张患者中,支气管扩张严重指数似乎可预测 1 年的死亡率。然而,它低估了 1 年和 4 年的加重率。因此,BSI 可能不适用于印度支气管扩张患者的预后工具。可能需要更大规模的多中心研究来进一步评估 BSI 在印度人群中的临床应用价值。